Cell kinetics of pleomorphic adenomas of the parotid gland.

L. Matturri,A. Lavezzi,B. Biondo,M. Mantovani

DOI: https://doi.org/10.1016/0964-1955(95)00090-9

1996-05-01

European Journal of Cancer Part B Oral Oncology

Abstract:

What problem does this paper attempt to address?

Non-surgical treatment as an alternative for the management of central giant cell granuloma: a systematic review

Camila Camarini,Elen de Souza Tolentino,Elen de Souza Tolentino

DOI: https://doi.org/10.1007/s00784-021-04193-z

2021-10-01

Clinical Oral Investigations

Abstract:ObjectiveTo evaluate the effectiveness of non-surgical treatment as an alternative in the management of central giant cell granuloma (CGCG).Material and methodsA literature search was carried out in accordance with the PRISMA statement in order to answer the question "Are non-surgical treatments effective as an alternative in the treatment of CGCG?". Two examiners independently assessed eligibility, risk of bias, and extracted data, which included therapeutic protocol, side effects, and need for surgical supplementation.ResultsAmong 1712 studies, 15 were included, totaling 145 patients. Calcitonin, intralesional corticosteroids, and denosumab were the medications used. For calcitonin (n = 61), complete remission was found in 30 cases. For intralesional triamcinolone (n = 68), reduction in size was observed in most cases (n = 39). Four cases received subcutaneous denosumab and showed absence of active bone metabolism in the region, of which three presented ossification. Combination of drug therapies (n = 29) was reported in one study and included subcutaneous interferon and oral imatinib. More and less side effects were found for interferon and corticosteroids, respectively. Forty percent of patients required additional surgical treatment.ConclusionDespite the side effects presented and the need for additional surgery in some patients, in general, all non-surgical treatments could provide positive results as an alternative for the management of CGCG, especially with regard to reducing the size of the lesion.Clinical relevanceCGCG is a benign bone lesion that mainly affects young individuals. Although the most common therapy is surgery, its contraindication in some patients, the large extension, and high recurrence rate of the aggressive variant have led the search for non-surgical therapies.

dentistry, oral surgery & medicine
Central giant cell granuloma of the jaws—long-term clinical and radiological outcomes of surgical and pharmacological management

Tal Capucha,Andrei Krasovsky,Ragda Abdalla Aslan,Jiriys George Ginini,Dany Noy,Omri Emodi,Adi Rachmiel,Dekel Shilo

DOI: https://doi.org/10.1007/s00784-024-05585-7

2024-03-09

Clinical Oral Investigations

Abstract:To compare long-term results of different treatment modalities in central giant cell granuloma of the maxillofacial-skeleton. Primary resection may result in major defects. Alternative treatments include pharmacological agents. As yet there has been no consensus on the use of the variety of treatment options, and few studies have reported clarifying long-term results.

dentistry, oral surgery & medicine
Central Giant Cells Granuloma Recurrence After Denosumab Use: A Case Report.

Italo Oliveira BARBOSA,Beatriz Afonso CHILITI,Matheus Eiji Warikoda SHIBAKURA,Patricia Verónica AULESTIA-VIERA,Hudson Sá SODRÉ,Patricia Anaya SINHORINI,André Caroli ROCHA

DOI: https://doi.org/10.1016/j.oooo.2023.12.383

2024-06-07

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

Abstract:Central giant cell granuloma (CGCG) is an osteolytic jaw lesion of benign nature with an unknown etiology. Treatment decisions depend on factors like the lesion's behavior, location, extent, and the patient's age. This case report describes a 28-year-old patient with an expansive CGCG located in the left mandibular body and parasymphysis, leading to facial asymmetry. Initially, the patient received six intralesional injections of triamcinolone (20mg/ml). However, due to treatment failure, denosumab therapy (120 mg) was initiated and continued for 12 months.

dentistry, oral surgery & medicine
Clinical and Radiologic Response of Central Giant Cell Granuloma to Denosumab: A 6-Year Prospective Observational Study

Yoon Ji Jina Rhou,Che-Jen Wang,Minh Nguyen,Joel A. Vanderniet,Craig F. Munns,Hedley Coleman,James Kim,Deborah Jane Holmes-Walker,Lydia Lim,Christian M. Girgis

DOI: https://doi.org/10.1007/s00223-021-00935-z

2022-01-28

Calcified Tissue International

Abstract:Central giant cell granuloma (CGCG) is a rare lesion of the jaw occurring in young adults and adolescents. Surgery, the traditional mainstay of therapy, is associated with significant morbidity. Denosumab, a humanised monoclonal antibody to RANKL, is effective in a related entity, giant cell tumour of bone (GCTB), but experience in the more indolent CGCG is limited. This prospective observational study of all denosumab-treated CGCG at a tertiary referral centre (2015–2021) aimed to evaluate the safety, efficacy and recurrence risk using denosumab in CGCG at lower-frequency dosing than used for GCTB. All received standardised, time-limited courses of denosumab 120 mg with stepwise increase in dosing interval based on response. They were followed for up to 75 months using a radiation-minimising protocol: 3-monthly clinical, biochemical and radiological assessment (orthopantomograms, cone beam CT). Eight patients, median age 20.5 years [IQR 6], received 13 initial doses [IQR 10] of denosumab 120 mg. Radiologic response was seen after 5.5 doses [IQR 4.5]: ossification in all and size reduction in three. Recurrence occurred in four of seven completing therapy, observed 12 months post-cessation [IQR 6.5]. Larger baseline size, aggressive subtype and fewer than 12 initial doses were more common in the recurrence group. There was no osteonecrosis of the jaw. Hypocalcaemia occurred in one receiving modified dosing. This study represents the largest, most diverse cohort of denosumab-treated CGCG with the longest follow-up in literature. It demonstrates the efficacy of lower-frequency, time-restricted course of denosumab but highlights the risk of recurrence. Long-term follow-up is critical.

endocrinology & metabolism
[Central Giant Cell Lesions of the Jaws: a Clinicopathological Study of 31 Cases].

Bo Liu,Shi-feng Yu,Yun-tang Wu,Shu-zhen Pang

DOI: https://doi.org/10.3760/j.issn:1002-0098.2005.01.021

2005-01-01

Abstract:OBJECTIVE:To study the clinicopathologic features of central giant cell granuloma (CGCG) of the jaws and the relationship between the pathologic features and its clinical behavior.METHODS:Histologic, radiographic and follow-up information for 31 cases of central giant cell granuloma were reviewed. The histopathologic patterns were analyzed between nonrecurrent and recurrent cases for which the following-up information was available.RESULTS:The majority of the giant cell granuloma of the jaws occurred in patients under 30 with a predilection of females and mostly were involved in the mandible. The radiographic features of CGCG non-specific. The multinucleated giant cell scattered unevenly, the numbers of the nuclei were few and mostly 10-19. The marked fibrosis, the multiple area of hemorrhage, abundant hemosiderin and newly formed bone were always present in the lesions. No significant difference exited between the recurrence and nonrecurrence groups in the pathologic features. The patients with aggressive behavior showed more consistent with the recurrence.CONCLUSIONS:CGCG was a non-neoplastic lesion of the jaws which was different from the giant cell tumor. It was difficult to distinguish between the CGCG and giant cell tumor (GCT), and to predict its clinical behavior only by the histopathological patterns. It was helpful to combine the clinical presentation of CGCG with its treatment.
Central Giant Cell Granuloma of the Mandible and Maxilla: A Clinicopathological Study of 21 Cases

Ahmed Lazim,Fnu Sakshi,Samir M Amer,Vinay S Mallikarjuna,Dina Zenezan,Riya Kuklani,Daniela Proca

DOI: https://doi.org/10.7759/cureus.63043

2024-06-24

Cureus

Abstract:Background Central giant cell granuloma (CGCG) presents as a locally invasive, intraosseous lesion characterized by the accumulation of multinucleated giant cells amidst a matrix of hemorrhage and reactive fibrous tissue that infiltrates bone trabeculae. This idiopathic non-neoplastic proliferative lesion primarily affects the mandible, typically presenting as either unilocular or multilocular radiolucencies on X-rays. Although trauma or intraosseous hemorrhages are potential triggers, the precise histogenesis and etiology remain unclear. CGCG predominantly occurs in children and young adults, with a slight female predilection. Methods and materials A retrospective analysis of 21 cases of CGCG diagnosed at the Oral Pathology/Pathology department of Temple University Hospital between 2015 and 2022 was conducted. Each case was evaluated based on various parameters, including age, gender, presenting symptoms, radiographic findings, clinical differential diagnosis, and histological confirmation. The primary radiographic technique employed for diagnosis was X-ray imaging of the mandible and maxilla. The histological examination involved cutting paraffin-embedded tissue into 5-micrometer-thick sections, which were then stained using routine hematoxylin and eosin (H&E) stain. Notably, no specialized histochemical or immunohistochemical stains were utilized in the evaluation process. Results In our study, we reviewed 21 cases; 9 were male, 11 were female, and one had no available gender data. The age range was 15-76 years, with a mean of 50 years. The mandible was the most commonly affected location (17 cases; 81%) while the maxilla was less commonly involved (4 cases; 19%). Many CGCG lesions were asymptomatic (13 cases; 62%); eight cases (38%) were symptomatic, with pain and fullness of the affected dental region being the main manifestations. In a few cases, conditions such as brown tumor (severe hyperparathyroidism) and odontogenic neoplasms, such as ameloblastoma, were suspected clinically and radiographically. The diagnosis of CGCG with associated acute and chronic inflammation was confirmed in all the cases. Histological evaluation of routinely stained slides was the main diagnostic tool utilized. No special stains or molecular studies were required to establish the final diagnosis. Conclusions Our investigation has determined that CGCG exhibits a non-neoplastic nature, displaying a spectrum of behaviors ranging from non-aggressive to aggressive tendencies. While CGCG is predominantly observed in the mandible, rare instances of involvement in the maxilla have also been documented. Importantly, no confirmed association with neoplastic lesions was identified during our analysis. The clinical course of CGCG tends to be indolent, with some cases presenting in association with impacted teeth. It's noteworthy that CGCG can present features mimicking neoplastic conditions, such as ameloblastoma, or localized lesions linked to systemic disorders such as hyperparathyroidism (brown tumor).
Treatment Management In Young Patient With Corticosteroid In Central Giant Cell Lesion.

Carlos Henrique Horst BIANCHIN,Maria Eduarda Schiestl MELO,João Victor Uchôa SILVA,Lara Thais Coelho ARAUJO,Heitor Fontes da SILVA

DOI: https://doi.org/10.1016/j.oooo.2023.12.370

2024-06-07

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

Abstract:A 26-year-old woman presented to the Oral and Maxillofacial Surgery Service, reporting an increase in volume in the anterior region of her mandible. Upon intraoral examination, a hardened edema was observed in the mandibular vestibule, along with tenderness upon palpation, moderate mobility in the anterior teeth, and noticeable mentual asymmetry. The patient had undergone a panoramic radiography six months prior, which revealed a radiolucent lesion crossing the mandibular midline. The lesion displayed well-defined areas, causing disruption to both the buccal and lingual corticals, without any displacement or root resorption of adjacent teeth.

dentistry, oral surgery & medicine
Histological Assessment of Extensive or Unresectable Central Giant Cell Granulomas Treated with Denosumab – A Case Series

Vinod Patel,Mahesh Kumar,Andrew Schache,Keith D Hunter,Barbara Carey,Simon N Rogers,Mustansir Alibhai,Selvam Thavaraj

DOI: https://doi.org/10.1016/j.oooo.2024.11.086

2024-11-29

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

Abstract:: The management of large central giant cell granuloma (CGCG) can pose a significant surgical challenge. In such circumstances the use of denosumab has been proposed with the literature reporting varying degrees of success. Histopathological assessment of CGCG post-denosumab treatment remains unknown. The current case series aims to address this lack of information and supplement the literature and the debate with evidence.

dentistry, oral surgery & medicine
Exploring Denosumab in the Treatment of Giant Cell Tumors: Clinical Evidence and Controversies

Baylee M. Brochu,Nicholas A. Mirsky,Vasudev Vivekanand Nayak,Lukasz Witek,Seth R. Thaller,Joao L. Carlini,Paulo G. Coelho

DOI: https://doi.org/10.1097/scs.0000000000010880

2024-11-18

Journal of Craniofacial Surgery

Abstract:Giant cell tumors (GCTs) are benign but locally aggressive bone neoplasms that primarily affect skeletally mature individuals. They are characterized by a tendency for recurrence and being associated with significant morbidity. Traditional treatment has focused on surgical resection; however, the role of medical therapies, such as Denosumab, a bone anti-resorptive drug, which has been Food and Drug Administration (FDA)-approved for unresectable GCTs since 2013, recently has gained prominence. Denosumab is a human monoclonal antibody that inhibits receptor activator of nuclear factor kappa B ligand (RANKL). This article aims to consolidate the current literature on Denosumab's efficacy in treating GCTs, highlighting its mechanism of action, clinical evidence, and potential complications. Clinical studies have demonstrated that Denosumab effectively reduces tumor size improving patient outcomes. Yet, some clinicians maintain concerns and reservations regarding local recurrence and malignant transformation. This review discusses the biochemical background of GCTs, current treatment guidelines, challenges, and future directions for research. Ultimately, Denosumab represents a potentially viable advancement in the management of GCTs, particularly in cases where surgical options are limited.

surgery
Treatment Of Aggressive Central Giant Cell Lesion In A Young Patient: A Case Report.

Nicoly Ghilardi CARDOSO,Mariana de Souza LESSA,João Paulo Stanislovicz PROHNY,Fernando Luiz ZANFERRARI,Bruna da Fonseca WASTNER,Laurindo Moacir SASSI,Juliana Lucena SCHUSSEL

DOI: https://doi.org/10.1016/j.oooo.2023.12.332

2024-06-07

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

Abstract:Central giant cell lesion (CGCL) is an uncommon, non-neoplastic bone condition that primarily affects the jawbones, exhibiting a wide range of behaviors and a high recurrence rate. We present the case of a 16-year-old male patient who complained of a chin swelling following a history of facial trauma. Clinical examination revealed both extraoral and intraoral swelling in the anterior region of the mandible. Imaging examinations showed a radiolucent, unilocular lesion with well-defined margins, measuring approximately 40 mm in diameter and causing cortical bone expansion.

dentistry, oral surgery & medicine
Combined endovascular therapy and surgery for central giant cell granuloma in the temporal bone: A case report

Takayuki Morimoto,Sung-Chul Ko,Keiji Shimada,Toshikazu Nishioka,Hidemori Tokunaga

DOI: https://doi.org/10.25259/SNI_487_2024

2024-09-20

Abstract:Background: Central giant cell granuloma (CGCG) is an uncommon, benign intraosseous lesion that most frequently occurs in the mandible and maxilla. Case description: A 31-year-old female with a medical history of Kawasaki disease presented to our hospital complaining of a clogged right ear. Head computed tomography revealed a mass in the squamous part of the right temporal bone, with osteolytic changes and invasion of the external auditory canal, middle ear, temporomandibular joint, and mastoid air cells. Enhanced magnetic resonance imaging (MRI) showed a strong signal in the intraosseous lesion. Digital subtraction angiography revealed tumor staining from multiple feeders, including the middle meningeal, posterior deep temporal, and posterior auricular arteries. Preoperative feeder embolization using a detachable coil and Embosphere Microspheres were performed for the middle meningeal artery under general anesthesia. After the endovascular treatment, we operated on the temporal bone lesion. Postoperative enhanced MRI showed subtotal resection and residual tumor near the external auditory canal, which was left in place to prevent opening the external auditory canal. The histopathological examination showed proliferation of mononuclear cells intermingled with osteoclast-like multinucleated giant cells. A diagnosis of CGCG was made. The postoperative course was uncomplicated, and the patient was discharged on day 10 of hospitalization. Conclusion: We reported a rare case of CGCG in the temporal bone, managed by endovascular therapy and surgical resection. This combination therapy resulted in subtotal resection, preserving surrounding normal structures, such as the external auditory canal and tympanic cavity.
Genetic variation and covariation for ewe reproduction, lamb growth, and lamb scrotal circumference in a fall-lambing sheep flock.

S. Al-Shorepy,D. Notter

DOI: https://doi.org/10.2527/1996.7471490X

1996-07-01

Journal of Animal Science

Abstract:Genetic parameters for female reproduction, lamb growth, and lamb scrotal circumference in a composite population of 50% Dorset, 25% Rambouillet and 25% Finnsheep breeding selected for ability to lamb in fall were estimated by REML using various animal models. Traits considered were spring fertility, litter size, weight at weaning (WWT), 90 d (WT90), and 120 d (WT120), and scrotal circumference at weaning (WSC), 90 d (SC90), and 120 d (SC120). Fertility was defined as 1 or 0 for ewes that lambed or failed to lamb, respectively, in fall and averaged .59 for adults (3 yr and older), .45 for second-lambing ewes, .18 for 19-mo-old ewes, and .11 for 12-mo-old ewes. Heritability estimates for fertility varied among models from .07 to .11. Heritability of fall litter size was .10. For body weights, estimates of additive direct, additive maternal, permanent environmental maternal, and litter effects as proportions of phenotypic variance were .04, .10, .05, and .11, respectively, for WWT, .09, .05, .14, and .01 for WT90, and .18, .0, .13, and .06 for WT120. Heritability estimates for WSC, SC90, and SC120 were .15, .25, and .02, respectively. Estimates of genetic correlations among body weights ranged from .77 to unity. Estimates of genetic correlations of fertility with fall litter size, WT90, and SC90 were .56, -.31, and .29, respectively. Genetic correlations of fall litter size with WT90 and SC90 were .33 and .36, respectively. Estimated genetic correlations revealed no major genetic antagonisms with ability to lamb in fall.
Concomitant Central Giant Cell Granuloma and Aneurysmal Bone Cyst in a Young Child

Deepika Pai,Abhay Taranath Kamath,Adarsh Kudva,Monica Monica Charlotte Solomon,Saurabh Kumar,Prem Sasikumar

DOI: https://doi.org/10.1155/2017/6545848

2017-01-01

Case Reports in Dentistry

Abstract:Although Central Giant Cell Granuloma (CGCG) is a benign tumor of the jaw and aneurysmal bone cyst seen in children, its aggressive behavior causes extensive loss of hard tissue requiring wide excision and extensive rehabilitation. We report a rare case of concomitant CGCG and aneurysmal bone cyst in a two-year-old male child, involving the coronoid and condylar process. Young age, large tumor, its aggressive nature, and future growth of orofacial region pose a significant challenge in the management of such conditions. For a successful outcome, the systematic approach to the presurgical evaluation and appropriate treatment planning is essential for such conditions.
Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence

Aneta Maria Borkowska,Anna Szumera-Ciećkiewicz,Bartłomiej Szostakowski,Andrzej Pieńkowski,Piotr Lukasz Rutkowski

DOI: https://doi.org/10.3390/cancers14092290

2022-05-05

Cancers

Abstract:(1) Despite the benign nature of the giant cell tumor of bone (GCTB), it shows a local recurrence rate of up to 50% and a chance of malignant transformation. The widely accepted local therapy in extremity GCTB is surgery, in the form of extended intralesional curettage with adequate disease clearance and retention of the limb, wherever possible. Denosumab, a human monoclonal antibody directed against the RANKL and associated inhibition of the RANKL pathway, is a relevant therapy option for advanced GCTB, to benefit tumor response and surgical down-staging. (2) The literature review of patients with GCTB treated with denosumab is performed via PubMed, using suitable keywords from January 2009 to January 2021. (3) Current indications for denosumab use are not definitively clear and unambiguous. Most GCTB patients with localized disease can be successfully treated with surgical curettage, and the role of denosumab in preoperative therapy in this patient population remains unclear. (4) However, patients with primary unresectable lesions or metastases may experience long-term clinical and radiological remission and pain control with denosumab treatment, and in this clinical situation, denosumab is currently the treatment of choice.

oncology
Effect of Bisphosphonates on Local Recurrence of Giant Cell Tumor of Bone: a Meta-Analysis.

Mingmin Shi,Lei Chen,Yangxin Wang,Wei Wang,Yujie Zhang,Shigui Yan

DOI: https://doi.org/10.2147/cmar.s187316

2019-01-01

Cancer Management and Research

Abstract:Background: Giant cell tumor of bone (GCTB) is a locally aggressive tumor, and its postoperative recurrence remains a problem. The present meta-analysis aimed to analyze the effect of bisphosphonates (BPs) on local recurrence of GCTB. Methods: Seven case-control studies were included by computerized searches of bibliographic databases (PubMed, AMED, EMBASE, the Cochrane library, ISI Web of Science, and China National Knowledge Infrastructure). The pooled adjusted ORs were calculated to evaluate the local recurrence of GCTB. Results: The BP group presented significantly lower total local recurrence rate than the control group in GCTB (P<0.01). Subgroup analysis shows BP group presented significantly lower local recurrence than the control group in GCTB with different tumor grades (P<0.05). In patients who underwent intralesional curettage, a significantly lower local recurrence rate was found in the BP group compared with the control group (P<0.01), but no significance was found for patients who underwent wide resection (P=0.16). None of the included studies described severe adverse effects related to BPs. Conclusion: The results confirmed the effect of BPs on reducing the local recurrence of GCTB, and the effect is not influenced by the tumor grades. BPs are benefit for the patients who underwent intralesional curettage but not recommended for those who underwent wide resection.
Efficacy of recombinant activated factor VII in unselected patients with uncontrolled haemorrhage: a single centre experience

Elspeth M. Payne,S. Brett,M. Laffan

DOI: https://doi.org/10.1097/01.mbc.0000233370.49099.c0

2006-07-01

Abstract:Recombinant activated factor VII (rFVIIa /Novoseven) has been used in a wide variety of circumstances as a treatment for uncontrolled bleeding. We present a retrospective report of the use of rFVIIa in 40 consecutive patients without inherited bleeding disorders in a single centre. Twenty-one (68%) of the 31 patients whose response to rFVIIa was documented showed a reduction or cessation in bleeding; in nine patients (29%) bleeding was unchanged and in one patient (3%) bleeding increased despite rFVIIa. One person suffered a thrombotic stroke after rFVIIa treatment. There were no other adverse events directly attributable to rFVIIa. Twenty-four patients (60%) died during the hospital admission in which the rFVIIa was administered. Twelve patients (30%) who received rFVIIa had bleeding secondary to haematological malignancy and 21 patients (53%) had bleeding complicating a surgical procedure. There were 11 deaths (92%) in the haematological malignancy group and 10 deaths (48%) in the surgical group. Patients with haematological malignancy received a significantly greater median number of doses of rFVIIa than patients with surgical bleeding complications (three versus one dose, P = 0.04). We conclude that rFVIIa can be used safely in uncontrolled haemorrhage and the majority of patients show a response.
Functional Outcomes of Limb Salvage Surgery in Patients with Giant Cell Tumor of Bone of the Lower Extremities: A Cross-sectional Comparative Study

Daniela Kristina D Carolino,Abigail R Tud

DOI: https://doi.org/10.47895/amp.vi0.7795

2024-08-15

Abstract:Background and objectives: Giant cell tumor of bone (GCTB) is a benign aggressive tumor primarily treated with surgery. Neoadjuvant treatment with denosumab or zoledronic acid is a common adjunct given to down-stage tumors and facilitate limb sparing surgery. This study sought to determine the characteristics, outcomes, and occurrence of complications following resection (RS) or extended curettage (EC) for GCTB of the lower extremities. Correlation of neoadjuvant therapy with the occurrence of complications was also investigated. Methods: This is an analytical cross-sectional study of 30 patients diagnosed with GCTB of the lower extremity treated between 2015 to 2022 in a single tertiary hospital. Functional outcomes were determined using the 1993 version of the Musculoskeletal Tumor Society (MSTS) score. Mean follow-up for all patients was 2.6 years (SD 1.8). Twenty-two patients (73%) underwent resection, while eight (27%) patients underwent extended curettage. Of the 30 patients, 26 (87%) patients received neoadjuvant therapy, with 21 (81%) given denosumab and five (19%) given zoledronic acid. Results: Functional outcomes were excellent for 23 patients (77%), with no significant difference between RS and EC groups. Nine complications occurred in the RS group, including dehiscence (n=3), superficial infection (n=2), implant failure (n=1), nonunion (n=1), palsy (n=1), and implant irritation (n=1). Five complications occurred in the EC group, four of which were noted to be recurrences, with one case of deep infection. Recurrence was noted to be significantly higher (p=0.0004) in the EC group. Separate correlation analysis showed no significant difference in incidence of complications but found that duration of surgery was significantly longer (p=0.0001), and intraoperative blood loss was significantly higher (p=0.0072) in the RS group. No significant difference (p=0.78) was noted in complication rate between patients given denosumab versus zoledronic acid. Conclusions: Functional outcomes of EC and RS appear to be comparable, including the incidence of complications. However, recurrence was noted to be significantly higher in EC. There appears to be no clear advantage between denosumab or zoledronic acid for GCTB. As a neoadjuvant medication and/or to control tumor progression, zoledronic acid may be the more economic option especially for patients in developing countries.
Giant Cell Granuloma In Maxilla: A Case Report.

Alana Gabrieli VOUK,Acir José DISCHAMBLE,Grasiele de Oliveira RAMOS,João Armando BRANCHER,Marilisa Carneiro Leão GABARDO,Eugênio Esteves COSTA

DOI: https://doi.org/10.1016/j.oooo.2023.12.290

2024-06-07

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

Abstract:Giant cell granuloma represents 7% of all benign tumors of gnathic bones, with a predilection for women. The non-aggressive type is the most common. The management of these lesions depends on their level of aggression, size, and location. In the clinical case presented, a 22-year-old female patient was referred due to a radiographic finding of a radiolucent lesion apparently associated with the roots of vital teeth 12 and 13. This lesion exhibited a volumetric increase on the buccal surface, was firm to palpation, and painless.

dentistry, oral surgery & medicine
Giant cell granuloma of the jaws: From molecular drivers to channelopathies

Ricardo Santiago Gomez

DOI: https://doi.org/10.1111/jop.13528

2024-03-18

Journal of Oral Pathology and Medicine

Abstract:Journal of Oral Pathology &Medicine, Volume 53, Issue 3, Page 169-171, March 2024.

dentistry, oral surgery & medicine,pathology
Current management of giant cell arteritis and its complications

Elena Galli,Francesco Muratore,Kenneth J Warrington

DOI: https://doi.org/10.1097/BOR.0000000000001029

2024-09-01

Abstract:Purpose of review: This review provides an update on current management strategies for giant cell arteritis (GCA), emphasizing the need for alternative therapies to reduce disease relapses and mitigate glucocorticoid (GC)-related morbidity. Recent findings: The standard of care for GCA has traditionally involved prolonged use of GC, and recent studies are exploring faster GC tapering regimens in an effort to reduce adverse effects while maintaining disease control. Randomized clinical trials have highlighted the efficacy of tocilizumab (TCZ), an interleukin-6 receptor inhibitor, in reducing disease flares and sparing GCs. However, the optimal treatment duration with TCZ is unknown and patients remain at risk of relapse after treatment discontinuation. An unmet therapeutic need persists for patients who are not candidates for TCZ, and for those who have inadequate response to this biologic. Therefore, investigations into alternative therapies such as targeting interleukin-17A, blocking T-cell activation or inhibiting the Janus kinase-signal transducer and activator of transcription pathway, showcase potential avenues for tailored treatments. Summary: While GCs remain the cornerstone of therapy, TCZ emerges as a promising GC-sparing agent. Ongoing research targeting different pathways implicated in GCA pathogenesis have led to encouraging results. However, the preliminary nature of these findings necessitates larger randomized controlled trials to establish their efficacy conclusively.

Cell kinetics of pleomorphic adenomas of the parotid gland.

Non-surgical treatment as an alternative for the management of central giant cell granuloma: a systematic review

Central giant cell granuloma of the jaws—long-term clinical and radiological outcomes of surgical and pharmacological management

Central Giant Cells Granuloma Recurrence After Denosumab Use: A Case Report.

Clinical and Radiologic Response of Central Giant Cell Granuloma to Denosumab: A 6-Year Prospective Observational Study

[Central Giant Cell Lesions of the Jaws: a Clinicopathological Study of 31 Cases].

Central Giant Cell Granuloma of the Mandible and Maxilla: A Clinicopathological Study of 21 Cases

Treatment Management In Young Patient With Corticosteroid In Central Giant Cell Lesion.

Histological Assessment of Extensive or Unresectable Central Giant Cell Granulomas Treated with Denosumab – A Case Series

Exploring Denosumab in the Treatment of Giant Cell Tumors: Clinical Evidence and Controversies

Treatment Of Aggressive Central Giant Cell Lesion In A Young Patient: A Case Report.

Combined endovascular therapy and surgery for central giant cell granuloma in the temporal bone: A case report

Genetic variation and covariation for ewe reproduction, lamb growth, and lamb scrotal circumference in a fall-lambing sheep flock.

Concomitant Central Giant Cell Granuloma and Aneurysmal Bone Cyst in a Young Child

Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence

Effect of Bisphosphonates on Local Recurrence of Giant Cell Tumor of Bone: a Meta-Analysis.

Efficacy of recombinant activated factor VII in unselected patients with uncontrolled haemorrhage: a single centre experience

Functional Outcomes of Limb Salvage Surgery in Patients with Giant Cell Tumor of Bone of the Lower Extremities: A Cross-sectional Comparative Study

Giant Cell Granuloma In Maxilla: A Case Report.

Giant cell granuloma of the jaws: From molecular drivers to channelopathies

Current management of giant cell arteritis and its complications